Pancreatic Ductal Adenocarcinoma (PDAC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Pancreatic
Ductal Adenocarcinoma (PDAC) Market Outlook
Thelansis’s “Pancreatic Ductal
Adenocarcinoma (PDAC) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Pancreatic Ductal Adenocarcinoma (PDAC) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Pancreatic
Ductal Adenocarcinoma (PDAC) Overview
Pancreatic
ductal adenocarcinoma (PDAC) is an aggressive malignancy arising from the
exocrine epithelium of the pancreatic ducts, representing the vast majority of
pancreatic cancers and carrying one of the poorest prognoses across all solid
tumours. Its pathobiology is driven by a stepwise accumulation of somatic
mutations — most critically activating KRAS mutations present in over 90% of
cases — alongside inactivation of tumour suppressor genes including CDKN2A,
TP53, and SMAD4, fostering unchecked cellular proliferation within a densely
immunosuppressive, desmoplastic stroma that impedes drug delivery and immune
surveillance. Clinically, PDAC is notoriously insidious; early disease is
largely asymptomatic, with patients typically presenting at advanced stages
with painless obstructive jaundice, profound unintentional weight loss,
new-onset or worsening diabetes, epigastric pain radiating to the back, and
cancer-associated thrombosis. Diagnostic workup incorporates contrast-enhanced
CT for staging and resectability assessment, supplemented by endoscopic
ultrasound-guided biopsy for tissue confirmation, while CA 19-9 serves as a
clinically useful — though non-specific — serum tumour marker for monitoring.
Surgical resection via pancreaticoduodenectomy remains the only potentially
curative option, yet fewer than 20% of patients present with resectable
disease; adjuvant chemotherapy with mFOLFIRINOX or gemcitabine-capecitabine is
standard following resection. For locally advanced or metastatic disease, systemic
chemotherapy with FOLFIRINOX or gemcitabine-nab-paclitaxel constitutes
first-line palliation, with germline BRCA-mutated patients deriving benefit
from PARP inhibitor maintenance therapy. Prognosis remains sobering, with
five-year survival below 15% overall; optimal management demands early
palliative care integration, nutritional support, pain management, and
compassionate shared decision-making centred on preserving dignity and quality
of life throughout the disease trajectory.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment